Idogen is preparing to start the clinical phase 1/2a study with IDO 8 in Norway
Idogen AB (publ) is working intensively on the preparations for the company's first clinical study with the cell therapy IDO 8 in patients with severe hemophilia A and is meeting a great deal of commitment at participating study centers. In Norway, the company's clinical trial center has come a long way in preparations for the study.
Idogen has previously received approval from both the Swedish and the Norwegian Medicines Agency to start the study, and in Norway, patients who are suitable for inclusion have now been identified. Professor Pål Andre Holme, senior physician at Oslo University Hospital and clinical investigator in Idogen's study, says in an interview with BioStock that he expects to soon be able to start the study and hopes to start after the summer. What remains in Norway is an approval from the local ethics committee.
"Idogen's cell therapy is a completely new type of treatment that we hope will enable many hemophilia A patients to once again benefit from FVIII treatment, which would have very positive consequences. I look forward to seeing the results of the phase 1/2a study,” he says and continues:
"In Norway, we will primarily initiate the treatment on one patient, which is expected to be carried out shortly, hopefully shortly after the summer".
"The strong interest we are seeing for our phase 1/2a study with IDO 8 is incredibly motivating for me and the entire Idogen development team. We have succeeded in recruiting leading centers - both in the Nordics and in other parts of Europe. With these centers on board, we gather broad expertise in the treatment of severe hemophilia A with antibodies against FVIII. It is very gratifying to meet their commitment to our study with IDO 8 and their hopes for this new and unique treatment method", says Anders Karlsson, CEO of Idogen.
The approvals the company received to start the study in Sweden and Norway are now being used to obtain a combined approval that includes all countries in the EU. For the UK, the approval process is based on the work done previously in Sweden and Norway.
Read a longer interview with Professor Pål Andre Holme, chief physician at Oslo University Hospital and clinical investigator in Idogen's study, as well as Dag Josefsen who is chief physician and head of section at the cell therapy department, in BioStock's article published today, Friday, Norwegian doctors prepare for Idogen's study - BioStock
For further information, please contact:
Anders Karlsson, CEO, Idogen AB
Phone: +46 70 918 00 10
Email: anders.karlsson@idogen.com
Certified Adviser:
The companies Certified Adviser is Vator Securities AB. Contact information : Vator Securities AB, Kungsgatan 34, SE-111 35 Stockholm, Email: ca@vatorsec.se. Tel: +46 (0)8-580 065 99
The information was submitted for publication, through the agency of the contact persons set out above, on 29 July 2022 at 08:44 CET.
The English text is an unofficial translation of the original Swedish text. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail.
Idogen (Nasdaq First Growth Market: IDOGEN) develops tolerogenic cell therapies to prevent the patient’s immune system from attacking biological agents, transplanted organs or the body's own cells or tissue. The company’s most advanced project, IDO 8, is designed to restore the efficacy of hemophilia drugs in patients who have developed neutralizing antibodies. The company’s second project, IDO T, is being developed to prevent kidney transplant rejection. In a third programme, IDO AID, Idogen is focused on the treatment of autoimmune diseases. The treatment for all indications is based on the patient's own
cells and is expected to have a favorable safety profile and long-lasting effect. The potential for a short-term treatment intervention to yield a long-term effect is a major advantage in health economics for both patients and divisions providing care. More information about Idogen is available via https://www.idogen.com